Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 15/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 14/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.34 |
| ▸ | RXRA | P19793 | 4/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16974641 | 0.88 | F11 (0.37) | F11KLKB1CYP3A4F2F10 | |
| SCHEMBL31252407 | 0.83 | F11 (0.44) | F11KLKB1CYP3A4F2F10 | |
| SCHEMBL16972221 | 0.82 | RXRA (0.33) | F11KLKB1CYP3A4RXRAGRIN1 | |
| SCHEMBL31252533 | 0.73 | F11 (0.38) | F11RXRAGRIN1GRIN2B | |
| SCHEMBL31174069 | 0.68 | F11 (0.43) | F11KLKB1CYP3A4F2PRSS1 | |
| SCHEMBL16983952 | 0.68 | F11 (0.43) | F11KLKB1CYP3A4F2PRSS1 | |
| SCHEMBL21357414 | 0.65 | F11 (0.51) | F11KLKB1CYP3A4F2F10 | |
| SCHEMBL24633487 | 0.65 | F11 (0.41) | F11KLKB1CYP3A4F2F10 | |
| SCHEMBL31174118 | 0.65 | F11 (0.44) | F11KLKB1CYP3A4F2F10 | |
| SCHEMBL24633398 | 0.65 | F11 (0.44) | F11KLKB1CYP3A4F2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3099686-B1 | MACROCYCLES WITH AROMATIC P2' GROUPS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-03-11 | — | — | EP | disclosed |
| US-20170096429-A1 | MACROCYCLES WITH AROMATIC P2' GROUPS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096429-A1 | MACROCYCLES WITH AROMATIC P2' GROUPS AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F2 | F11 6/4885KLKB1 19/4885CYP3A4 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.